NCT05784779招募中1 期
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)
1Globe Biomedical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2023年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Determine recommended Phase II dose (RP2D)
研究概览
简要总结
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •≥ 18 years of age and < 75 years old.
- •BMI ≥ 18 kg/m
- •Histologically confirmed NASH (defined as the presence of steatosis, inflammation, and ballooning) within 6 months prior to randomization with stage 2-3 fibrosis according to the NASH Clinical Research Network (CRN) classification OR NAFLD diagnosed by imaging assessment (MRI-PDFF ≥10% within 2 months prior to randomization).
- •≤ 5% weight change within 6 months prior to randomization.
- •Diagnosed with T2DM.
- •For male or female patient of childbearing potential: Must agree to use contraception or take measures to avoid pregnancy during the study, and for 30 days (female) or 90 days (male) after the last dose of GH509/placebo.
- •Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 5 days prior to randomization. The minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG.
- •Serum alanine transaminase (ALT) and serum aspartate transaminase (AST) ≤ 10×ULN within 14 days prior to randomization.
- •Serum creatinine <1.5×ULN within 14 days prior to randomization.
- •Platelets count ≥ 100,000/mm3 within 14 days prior to randomization.
排除标准
- •Subjects with a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening.
- •Use of injected or oral antidiabetic agents within 3 months including: Thiazolidinediones; Subcutaneously administered agents; Sodium-glucose co-transporter 2 inhibitors
- •Patients with a history of hypoglycemia within 3 months before study enrollment.
- •Subject uses drugs historically associated with NASH/NAFLD for more than 2 weeks in the year prior to randomization.
- •Treatment with a non-stable dose of statins, fibrates, or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 3 months prior to randomization.
- •LDL ≥190 mg/dL.
- •Treatment with a non-stable dose of drugs with potential anti-NASH/NAFLD effect in the 6 months prior to randomization.
- •Participated in a clinical research study with any investigational product being evaluated for the treatment of diabetes, weight loss, or NASH/NAFLD in the 6 months prior to randomization.
- •Subject is listed for orthotopic liver transplant (OLT) or has medical history of: biliary diversion, organ transplant/bone marrow transplant or undergoing immunosuppressive therapy, hepatocellular, pancreatic, thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2) or other malignant disease.
- •Subject has prior or has planned bariatric surgery.
- •Subject had major surgery within 8 weeks prior to randomization, significant traumatic injury, or anticipation of need for major surgical procedure during the course of the study.
- •Presence of cirrhosis on liver biopsy.
- •Model for End-stage Liver Disease (MELD) score greater than
- •Subject with clinical evidence of hepatic decompensation.
- •Subject has evidence of other forms of chronic liver disease:.
- •Acute cholecystitis or known biliary obstruction.
- •Acute or chronic pancreatitis or administration of total parenteral nutrition within 6 months prior to randomization.
- •Subject has gastrointestinal disorder(s) which would significantly impede the absorption of an oral agent.
- •Subject has concurrent severe infection including diagnoses of fever of unknown origin.
- •Clinically significant and uncontrolled cardiovascular disease within 12 months prior to randomization; cerebrovascular disease, grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication or grade II or greater peripheral vascular disease.
- •Subject with history of human immunodeficiency virus (HIV) infection.
- •Subject with known allergies to the study drug or any of its excipients.
- •Subject with an active, serious medical disease with likely life expectancy of less than 5 years.
- •Subject with active substance abuse, including alcohol and/or inhaled or injection drugs, in the year prior to randomization.
- •Subject has participated in an investigational new drug (IND) trial in the 30 days before randomization.
- •Subject has been previously exposed to GH
- •Unable or unwilling to swallow GH509/placebo daily.
- •Ineligibility for MRI.
- •Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
- •Subject has any other condition which would impede compliance or hinder completion of the study.
研究组 & 干预措施
GH509
Experimental
干预措施: GH509 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Determine recommended Phase II dose (RP2D)
时间窗: 12 weeks
Determine the recommended Phase II dose (RP2D) of GH509, which is defined as the dose level that is well tolerated by patients
Change in liver fat content as assessed by MRI-PDFF
时间窗: 12 weeks
Proportion of patients achieving ≥30% hepatic fat reduction (assessed by MRI-PDFF) from baseline after 12 weeks of treatment
次要结局
- Change in liver fat as assessed by MRI-PDFF(12 weeks)
- Change in weight control as assessed by weight loss(12 weeks)
- Change in liver enzymes as assessed by serum alanine aminotransferase (ALT)(12 weeks)
- Proportion of MRI-PDFF responders(12 weeks)
- Change in glycemic control as assessed by HbA1c(12 weeks)
- Change in glycemic control as assessed by fasting blood glucose (FBG)(12 weeks)
- Tolerability and safety as assessed by incidence of adverse events(16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Improved Novel VaccIne CombinaTion InflUenza StudyInfluenzaNCT03300362Barinthus Biotherapeutics862
招募中
2 期
A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHBHepatitis B, ChronicNCT05484466Shanghai Zhimeng Biopharma, Inc.90
已完成
2 期
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary HypertensionIdiopathic Pulmonary FibrosisNCT02951429Hoffmann-La Roche177
已完成
2 期
Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 DiabetesNew Onset Type-1 DiabetesNCT02005848Kamada, Ltd.70
已完成
2 期
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentChronic Spontaneous UrticariaNCT06228560Longbio Pharma202